Hyperprolactinémies d’origine médicamenteuse : étude cas/non-cas dans la banque nationale de pharmacovigilance

Petit, A; Piednoir, D.; Germain, M. L.; Trenque, Thierry

doi:10.2515/therapie:2003023

Cited by 21 publications

(10 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Based on cumulative case reports, all SSRIs have the potential to cause elevation of basal PRL. This observation was recently confirmed by the French Pharmacovigilance Database Study, an epidemiological study that investigated the rates of hyperprolactinemia induced by multiple prescription medications from 1985 to 2000 (Petit et al, 2003). Of the total of 159 cases of druginduced hyperprolactinemia, 17% had been induced by SSRIs, which included sertraline (OR ¼ odds ratio 15.74), fluoxetine (OR 49), paroxetine (OR 8.10), fluvoxamine (OR 5.96), and citalopram (OR 3.62).…”

Section: Clinical Relevance Of Ssri-induced Hyperprolactinemia: Emergmentioning

confidence: 71%

From Galactorrhea to Osteopenia: Rethinking Serotonin–Prolactin Interactions

Emiliano

Fudge

2004

Neuropsychopharmacol

View full text Add to dashboard Cite

The widespread use of the selective serotonin reuptake inhibitors (SSRIs) has been accompanied by numerous reports describing a potential association with hyperprolactinemia. Antipsychotics are commonly known to elevate serum prolactin (PRL) through blockade of dopamine receptors in the pituitary. However, there is little awareness of the mechanisms by which SSRIs stimulate PRL release. Hyperprolactinemia may result in overt symptoms such as galactorrhea, which may be accompanied by impaired fertility. Long-term clinical sequelae include decreased bone density and the possibility of an increased risk of breast cancer. Through literature review, we explore the possible pathways involved in serotonin-induced PRL release. While the classic mechanism of antipsychotic-induced hyperprolactinemia directly involves dopamine cells in the tuberoinfundibular pathway, SSRIs may act on this system indirectly through GABAergic neurons. Alternate pathways involve serotonin stimulation of vasoactive intestinal peptide (VIP) and oxytocin (OT) release. We conclude with a comprehensive review of clinical sequelae associated with hyperprolactinemia, and the potential role of SSRIs in this phenomenon.

show abstract

Section: Clinical Relevance Of Ssri-induced Hyperprolactinemia: Emergmentioning

confidence: 71%

From Galactorrhea to Osteopenia: Rethinking Serotonin–Prolactin Interactions

Emiliano

Fudge

2004

Neuropsychopharmacol

View full text Add to dashboard Cite

show abstract

“…Some studies did not specifically exclude individuals using antipsychotics [23, 31, 32], while others only noted that participants were free of other medications for at least one week prior to and during the study [22, 24-28], though this does not necessarily exclude use of such drugs in the recent past. Thus, the effects of concordant or recent use of antipsychotic medications on prolactin levels cannot be excluded as an explanation for reported increases associated with SSRI use in some studies [22, 24-26, 28, 31, 32]. However, two studies reporting significant prolactin increases associated with SSRI use specifically excluded individuals using antipsychotic medications [20, 21].…”

Section: Discussionmentioning

confidence: 99%

“…Prior evidence that SSRIs could increase prolactin levels are largely from clinical trials of these drugs, often with a fairly short duration of use ranging from 1 to 12 weeks [20, 22-28, 31, 32] and only one study over one year [21]. We lacked detailed information on duration of AD and SSRI use, as NHS and NHS2 participants self-reported AD use every two years and at the time of blood draw.…”

Section: Discussionmentioning

confidence: 99%

Antidepressant use and circulating prolactin levels

Reeves

Okereke

Qian

et al. 2016

Cancer Causes Control

View full text Add to dashboard Cite

Purpose Whether antidepressants (AD), specifically selective serotonin reuptake inhibitors (SSRIs), are linked to elevated prolactin levels among the general population is unknown. Methods Circulating prolactin levels were available on 4593 healthy participants in the Nurses’ Health Study (NHS) and NHS2, including 267 AD users. We fit generalized linear models to calculate and compare adjusted mean prolactin levels between AD users and non-users and further among SSRI users. Multivariable logistic regression was used to estimate odds ratios (ORs) and 95% confidence intervals (CIs) for “elevated” prolactin levels (>11 ng/mL) comparing AD users to non-users. We evaluated AD use and change in prolactin levels among 610 NHS participants with two measurements an average of 11 years apart. Results Adjusted geometric mean prolactin levels were similar among SSRI users (13.2 ng/mL, 95% CI 12.2-14.4), users of other classes of ADs (12.7 ng/mL, 95% CI 11.0-14.6), and non-users (13.1 ng/mL, 95% CI 12.8-13.4). Neither AD use (OR=1.17, 95% CI 0.89-1.53) nor SSRI use (OR=0.95, 95% CI 0.66-1.38) was associated with elevated prolactin levels. Change in prolactin levels was similar across women who started, stopped, consistently used, or never used ADs. Conclusions This study does not support the hypothesis that AD use would influence breast cancer risk via altered prolactin levels. These results provide some evidence that use of ADs to treat depression or other conditions may not substantially increase prolactin levels in the majority of women.

show abstract

“…Reduced DA transmission in the form of DA receptor blockade by antipsychotic treatment in schizophrenia is frequently manifested by the side effects of EPS and hyperprolactinemia, since dopamine exerts a potent and tonic inhibition of prolactin secretion under normal conditions (Kane, 2011). In a study of 159 patients on different medications, 27 cases (17%) of hyperprolactinemia were reported after SSRI treatment, and the occurrence was the highest for sertraline followed by paroxetine and other antidepressants (Petit et al , 2003). However, a more recent review of spontaneous reports suggested that paroxetine, but not sertraline or escitalopram, was associated with a higher risk of hyperprolactinemia (Trenque et al , 2011).…”

Section: Mechanisms Related To Efficacy and Tolerabilitymentioning

confidence: 99%

A comparative review of escitalopram, paroxetine, and sertraline

Sanchéz

Reines

Montgomery

2014

International Clinical Psychopharmacology

227

139

View full text Add to dashboard Cite

It is known that newer antidepressants, such as the selective serotonin reuptake inhibitors (SSRIs), provide advantages in tolerability over antidepressants such as the tricyclics. However, even within the SSRI class, differences in efficacy or tolerability exist between the individual drugs. Among the three most widely prescribed SSRIs are paroxetine, sertraline, and escitalopram. Escitalopram is commonly referred to as an SSRI, but also has well-documented allosteric properties, and thus can be further classed as an allosteric serotonin reuptake inhibitor. All three antidepressants are efficacious compared with placebo, but there is evidence that escitalopram is more effective than a range of other antidepressants. There are no direct data to regard either paroxetine or sertraline as a superior antidepressant. Escitalopram is superior compared with paroxetine, which has a less favorable tolerability profile. Paroxetine is associated with cholinergic muscarinic antagonism and potent inhibition of CYP2D6, and sertraline has moderate drug interaction issues in comparison with escitalopram. Overall, as an allosteric serotonin reuptake inhibitor that is somewhat different from classical SSRIs, escitalopram is the first choice judged by combined efficacy and tolerability, and nonclinical data have offered possible mechanisms through which escitalopram could be more efficacious, based on its interaction with orthosteric and allosteric binding sites at the serotonin transporter.

show abstract

Hyperprolactinémies d’origine médicamenteuse : étude cas/non-cas dans la banque nationale de pharmacovigilance

Cited by 21 publications

References 2 publications

From Galactorrhea to Osteopenia: Rethinking Serotonin–Prolactin Interactions

From Galactorrhea to Osteopenia: Rethinking Serotonin–Prolactin Interactions

Antidepressant use and circulating prolactin levels

A comparative review of escitalopram, paroxetine, and sertraline

Contact Info

Product

Resources

About